Mandate

Vinge advises Industrifonden on the investment in Aprea AB

November 07, 2007

Vinge advises Industrifonden on its investment in Aprea AB, a pharmaceutical company that develops and carries out research on a new drug against cancer. Aprea will raise MSEK 50 through this share issue of which Industrifonden contributes with MSEK 25 and will thereby become a new owner in the company.

Industrifonden is represented by partner Johan Winnerblad with assistance from Johan Larsson.

Related

Vinge has advised Investor in connection with acquisition of shares in EQT

Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026